X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Syneos Health will provide support in all pre-launch and launch activities for Zepizure (midazolam), an epileptic rescue therapy for epileptic seizures.
Lead Product(s): Midazolam
Therapeutic Area: Neurology Product Name: Zepizure
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Crossject
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 04, 2024
Details:
ONP-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of moderate traumatic brain injury. It crosses BBB & activates gene response leading to the production of proteins that reduce inflammation, oxidative stress, and swelling.
Lead Product(s): ONP-002
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PRV-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Odyssey Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 16, 2023
Details:
ITF2357 (givinostat) is an investigational drug act as a inhibits histone deacetylases (HDACs), which is investigated for the treatment of Duchenne Muscular Dystrophy.
Lead Product(s): Givinostat
Therapeutic Area: Genetic Disease Product Name: ITF2357
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: The Italfarmaco Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
The collaboration is for strategically and optimally progress development and commercialization of FivepHusion's enhanced chemotherapeutic formulation Deflexifol, an anti-cancer drug reformulation combining 5-fluorouracil and its biomodulator leucovorin, in global markets.
Lead Product(s): Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: Deflexifol
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: FivepHusion
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 26, 2023
Details:
CELZ-201 is the First Novel Allogenic Cellular Therapy in the Dorsal Artery of the Pancreas. CELZ-201 leverages unique approach harnessing the power of PRDC to multi-potentialities, including self-renewal ability, low antigenicity, reduced toxicity, without immunosuppression.
Lead Product(s): CELZ-201
Therapeutic Area: Endocrinology Product Name: CELZ-201
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Creative Medical Technology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 07, 2023
Details:
The partnership will support the global advancement of cell and gene therapies.The new partnership couples the full suite of clinical development services offered by Syneos Health with IntegriCell™, Cryoport's platform.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Recipient: Cryoport Systems Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 18, 2023
Details:
DaxibotulinumtoxinA for Injection, including Revance’s first oral presentation of the ASPEN-1 Phase 3 clinical trial data, the positive topline results from the ASPEN Open Label Study, which demonstrated long-term safety and efficacy of repeat treatments.
Lead Product(s): Daxibotulinumtoxin A
Therapeutic Area: Neurology Product Name: Daxxify
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Revance Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
Idorsia to capitalize upon the unique opportunity to transform the insomnia treatment paradigm, notably in Europe where daridorexant would be the first dual orexin receptor antagonist made available to patients with insomnia.
Lead Product(s): Daridorexant
Therapeutic Area: Sleep Product Name: Quviviq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Idorsia Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 26, 2022
Details:
Revance will present results from its ASPEN-1 Phase 3 clinical trial evaluating the efficacy and safety of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia in adults.
Lead Product(s): Daxibotulinumtoxin A
Therapeutic Area: Neurology Product Name: Daxxify
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Revance Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2021
Details:
Byondis is drafting plans to pursue commercialisation partners for when results from its Phase III breast cancer antibody-drug conjugate study are released in 2Q21.
Lead Product(s): Trastuzumab duocarmazine
Therapeutic Area: Oncology Product Name: SYD985
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Byondis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
